Reported Friday, Travere Says PROTECT Biomarker Data Add To Superior Proteinuria Reduction, Slower Kidney Function Decline Versus Irbesartan, Supporting FILSPARI As Non-Immunosuppressive, Kidney-Targeted, Foundational First-Line Treatment For IgA Nephropathy
FILSPARI achieved greater reductions in biomarkers linked to kidney inflammation and injury than maximum labeled dose irbesartanFindings provide further evidence of the biological effects of dual endothelin and
Travere's kidney medicine FILSPARI worked better than a standard treatment. Doctors can watch for this as a sign the company's drug might help more patients.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.